Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research, or SAKK, said Thursday that cancer drug candidate INT230-6 showed several benefits in a phase 2 trial in multiple tumor types, including triple negative breast cancer.

INT230-6, designed for direct intratumoral injection, leads to local disease control and direct tumor killing as well as has systemic anti-tumor effects, according to a joint statement.

Data from the study showed that INT230-6 has tumor-killing properties at levels greater than 95% in some patients treated with a single dose, as well as "significant" necrosis in tumors bigger than 2 cm in 74% of the patients at the time of surgery, the company and SAKK said.

Intensity and SAKK have also initiated a phase 2 study to assess the clinical activity, safety and tolerability of INT230-6 in patients with early-stage, operable triple negative breast cancer. Recruitment is ongoing, with a target to enroll 54 patients, and seven sites have been activated in Switzerland, they added.

Shares of Intensity Therapeutics fell more than 16% in recent trading.

Price: 1.97, Change: -0.38, Percent Change: -16.17